Baricitinib
16275
Phase 3 small_molecule active
Quick answer
Baricitinib for Systemic Juvenile Idiopathic Arthritis is a Phase 3 program (small_molecule) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly and Company
- Indication
- Systemic Juvenile Idiopathic Arthritis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active